JP6092843B2 - 神経障害の治療用組成物 - Google Patents

神経障害の治療用組成物 Download PDF

Info

Publication number
JP6092843B2
JP6092843B2 JP2014501739A JP2014501739A JP6092843B2 JP 6092843 B2 JP6092843 B2 JP 6092843B2 JP 2014501739 A JP2014501739 A JP 2014501739A JP 2014501739 A JP2014501739 A JP 2014501739A JP 6092843 B2 JP6092843 B2 JP 6092843B2
Authority
JP
Japan
Prior art keywords
acid
group
dose
composition
omega
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014501739A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014512351A5 (OSRAM
JP2014512351A (ja
Inventor
パンザリス・マリオス
パトリキオス・イオアニス
ルーカイディス・ゲオルギオス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Palupa Medical Ltd
Original Assignee
Palupa Medical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46275907&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6092843(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Palupa Medical Ltd filed Critical Palupa Medical Ltd
Publication of JP2014512351A publication Critical patent/JP2014512351A/ja
Publication of JP2014512351A5 publication Critical patent/JP2014512351A5/ja
Application granted granted Critical
Publication of JP6092843B2 publication Critical patent/JP6092843B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Steroid Compounds (AREA)
JP2014501739A 2011-03-29 2012-03-28 神経障害の治療用組成物 Expired - Fee Related JP6092843B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161469081P 2011-03-29 2011-03-29
US61/469,081 2011-03-29
PCT/IB2012/000824 WO2012131493A1 (en) 2011-03-29 2012-03-28 Compositions for the treatment of neurologic disorders

Publications (3)

Publication Number Publication Date
JP2014512351A JP2014512351A (ja) 2014-05-22
JP2014512351A5 JP2014512351A5 (OSRAM) 2015-05-14
JP6092843B2 true JP6092843B2 (ja) 2017-03-08

Family

ID=46275907

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014501739A Expired - Fee Related JP6092843B2 (ja) 2011-03-29 2012-03-28 神経障害の治療用組成物

Country Status (20)

Country Link
US (2) US20120252888A1 (OSRAM)
EP (1) EP2691086B1 (OSRAM)
JP (1) JP6092843B2 (OSRAM)
CN (1) CN104010634B (OSRAM)
AU (1) AU2012235869B2 (OSRAM)
BR (1) BR112013025088B1 (OSRAM)
CA (1) CA2831506C (OSRAM)
CY (1) CY1117828T1 (OSRAM)
DK (1) DK2691086T3 (OSRAM)
EA (1) EA025232B1 (OSRAM)
ES (1) ES2585066T3 (OSRAM)
GE (1) GEP201606568B (OSRAM)
HR (1) HRP20160939T1 (OSRAM)
HU (1) HUE028065T2 (OSRAM)
IL (1) IL228541A (OSRAM)
MX (1) MX2013011295A (OSRAM)
PL (1) PL2691086T3 (OSRAM)
UA (1) UA114706C2 (OSRAM)
WO (1) WO2012131493A1 (OSRAM)
ZA (1) ZA201307256B (OSRAM)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10709680B2 (en) * 2011-07-18 2020-07-14 Physicians Recommended Nutriceuticals, Llc Methods for treating dry eye
ITMI20130354A1 (it) * 2013-03-08 2014-09-09 Again Life Italia Srl Miscela di acidi grassi (f.a.g. fatty acids group) per uso nel trattamento di patologie infiammatorie.
CN105828816A (zh) * 2013-11-12 2016-08-03 雅培公司 包含天然维生素e和多不饱和脂肪酸的营养组合物的用途
EP3906920A1 (en) 2014-06-06 2021-11-10 Marine Ingredients, LLC Omega-3 compositions, dosage forms, and methods of use
KR20180004096A (ko) * 2014-07-11 2018-01-10 매뉴 졸리 배다캐무리 최적화 된 영양 지방산 조성
DE102015109352A1 (de) * 2015-06-12 2016-12-15 K. D. Pharma Bexbach Gmbh Anwendung von Omega-3- und/oder Omega-6-Fettsäure(n)
AR102008A1 (es) * 2015-09-24 2017-01-25 Brix S R L Ingrediente farmacéutico activo (ifa) oleoso para el tratamiento de afecciones de la piel, composiciones que lo comprenden y su uso para prepararlas
WO2017213490A1 (en) 2016-06-10 2017-12-14 N.V. Nutricia Method for controlling neuroinflammation
JP2019534329A (ja) 2016-11-04 2019-11-28 アイエムエムディー エスペー．ゾー．オー 摂取および吸収された分子の知的送達
CN109125311A (zh) * 2018-06-26 2019-01-04 东南大学 预防或治疗阿尔茨海默症的药物组合物及其应用
US20240165075A1 (en) * 2021-02-08 2024-05-23 Synaptogenix, Inc. Treatment of optic nerve inflammation using pkc activators
US20240180869A1 (en) * 2021-02-08 2024-06-06 Synaptogenix, Inc. Treatment of multiple sclerosis using pkc activators
AU2022328181A1 (en) * 2021-08-09 2024-03-21 Kentucky Equine Research, Inc. Compositions and methods for modulating equine fatty acid profiles

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601399D0 (en) * 1986-01-21 1986-02-26 Delta Iota Ltd Information transmission/processing
GB8601915D0 (en) * 1986-01-27 1986-03-05 Efamol Ltd Pharmaceutical compositions
GB8813766D0 (en) 1988-06-10 1988-07-13 Efamol Holdings Essential fatty acid compositions
GB9001121D0 (en) * 1990-01-18 1990-03-21 Efamol Holdings Efa compositions and therapy
PH31403A (en) * 1991-03-01 1998-10-29 Warner Lambert Co Therapeutic compositions to protect and recuscitate mammalian cells and methods for preparing same.
GB9111900D0 (en) * 1991-06-03 1991-07-24 Efamol Holdings Fatty acid compositions
JP3283274B2 (ja) * 1991-06-15 2002-05-20 サントリー株式会社 新規組成物
GB9506837D0 (en) * 1995-04-03 1995-05-24 Scotia Holdings Plc Triglycerides
DE19757414A1 (de) * 1997-12-23 1999-07-01 Nutricia Nv Fettmischung
US6048891A (en) * 1998-12-17 2000-04-11 Loma Linda University Medical Center Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of natriuretic disease
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
US6677321B1 (en) * 1999-12-09 2004-01-13 Bruce Levin Methods and compositions for treatment of inflammatory disease
US7045683B2 (en) 2001-05-04 2006-05-16 Abbott Laboratories Δ4-desaturase genes and uses thereof
ES2238568T3 (es) * 2001-05-30 2005-09-01 Laxdale Limited Uso del coenzima q (ubiquinona) y acido eicosapentaenoico (epa) para el tratamiento del linfoma no hodgkin y trastornos psiquiatricos o neurologicos.
ES2288193T3 (es) 2001-07-27 2008-01-01 NEPTUNE TECHNOLOGIES & BIORESSOURCES INC. Fosfolipidos naturales de origen marino que contienen flavonoides y fosfolipidos poliinsaturados y sus usos.
WO2003043570A2 (en) * 2001-11-15 2003-05-30 Galileo Laboratories, Inc. Formulations and methods for treatment or amelioration of inflammatory conditions
US20050080109A1 (en) 2003-10-09 2005-04-14 Papas Andreas M. Gamma-tocopherol and gamma-tocotrienol therapy for multiple sclerosis
KR101256448B1 (ko) * 2005-12-21 2013-04-19 브루디 테크놀로지 에스엘 세포의 산화적 손상과 연관된 병리상태를 치료하기 위한ｄｈａ, ｅｐａ 또는 ｄｈａ 유래의 ｅｐａ의 용도
US20090196862A1 (en) * 2008-01-22 2009-08-06 William Davis High dosage Vitamin D
JP2010155799A (ja) * 2008-12-26 2010-07-15 Fujifilm Corp 粉末組成物及びそれを含む食品
US9062275B2 (en) * 2009-04-17 2015-06-23 Natac Pharma, S.L. Compositions rich in omega-3 fatty acids with a low content in phytanic acid

Also Published As

Publication number Publication date
WO2012131493A1 (en) 2012-10-04
HUE028065T2 (en) 2016-11-28
EA025232B1 (ru) 2016-12-30
US20190343774A1 (en) 2019-11-14
EA201391407A1 (ru) 2014-03-31
ZA201307256B (en) 2014-12-23
ES2585066T3 (es) 2016-10-03
CY1117828T1 (el) 2017-05-17
AU2012235869B2 (en) 2017-04-20
BR112013025088A2 (pt) 2017-02-14
GEP201606568B (en) 2016-11-10
US20120252888A1 (en) 2012-10-04
EP2691086B1 (en) 2016-04-27
IL228541A0 (en) 2013-12-31
MX2013011295A (es) 2014-11-10
BR112013025088B1 (pt) 2021-12-14
UA114706C2 (uk) 2017-07-25
EP2691086A1 (en) 2014-02-05
AU2012235869A1 (en) 2013-10-17
CN104010634B (zh) 2017-06-09
CN104010634A (zh) 2014-08-27
DK2691086T3 (en) 2016-08-15
JP2014512351A (ja) 2014-05-22
HK1194665A1 (zh) 2014-10-24
CA2831506A1 (en) 2012-10-04
IL228541A (en) 2017-11-30
PL2691086T3 (pl) 2016-12-30
NZ616554A (en) 2015-10-30
CA2831506C (en) 2019-07-09
HRP20160939T1 (hr) 2016-10-07

Similar Documents

Publication Publication Date Title
JP6092843B2 (ja) 神経障害の治療用組成物
US10342773B2 (en) Composition containing dihomo-γ-linolenic acid (DGLA) as the active ingredient
US8563609B2 (en) Nitro fatty acids - neuroprotection and/or inhibition of cognitive decline
JP4986321B2 (ja) 炎症性状態処置のための方法および組成物
JP5697293B2 (ja) 器質的脳障害に起因する高次脳機能の低下に対する改善作用を有する組成物
CN101842103A (zh) 用于脑部健康的单位剂量
CA3172141A1 (en) Krill oil composition enriched in lpc-dha and lpc-epa
JP2008214338A (ja) 高次脳機能低下改善剤および遅延記憶低下改善剤
JP5769912B2 (ja) 認知障害を伴う疾患又は状態の予防又は治療用の組成物
JP6750831B2 (ja) 非アルコール性脂肪性肝疾患の処置
NZ616554B2 (en) Compositions for the treatment of neurologic disorders
JP2009019025A (ja) 非ヒト動物の老化又は痴呆に伴う疾患又は症状の改善剤
HK1194665B (en) Compositions for the treatment of neurologic disorders
US20150133554A1 (en) Purification of dpa enriched oil
JPWO2005046668A1 (ja) 言語障害予防・治療剤
JP6095615B2 (ja) 器質的脳障害に起因する高次脳機能の低下に対する改善作用を有する組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150326

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150326

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160202

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20160219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160315

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160816

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161215

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20161222

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170207

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170209

R150 Certificate of patent or registration of utility model

Ref document number: 6092843

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees